Ribociclib functions as a cyclin-dependent kinase 4/6 inhibitor for first-line therapy against HR+/HER2‒ advanced breast tumors, and its bioavailability is not influenced by gastric pH alterations or food intake[41]. Here, ERBB2 is linked to breast neoplasm.